Impact of a randomized trial on maintenance tocolysis on length of hospital admission of women with threatened preterm labor in The Netherlands

Thomas S. de Lange, Carolien Roos*, Kitty W. M. Bloemenkamp, Antoinette C. Bolte, Johannes J. J. Duvekot, Maureen T. M. Franssen, Marjolein Kok, Martijn A. Oudijk, Martina M. Porath, Joris A. M. van der Post, Ben Willem J. Mol

*Corresponding author voor dit werk

OnderzoeksoutputAcademicpeer review

6 Citaten (Scopus)

Samenvatting

Introduction: The APOSTEL-II trial was a multicenter randomized placebo-controlled trial, assessing the effectiveness of maintenance tocolysis with nifedipine. The trial showed maintenance tocolysis not to have an effect on perinatal outcome. Objective of the current study is to evaluate the effect of a negative trial on the length of hospital admission of women with threatened preterm labor.

Materials and methods: We evaluated length of hospital admission of all patients admitted with threatened preterm labor with a gestational age

Results: The mean length of hospital admission was 9.3 days before the start of the trial, 8.4 days during the recruitment period and 8.1 days after the trial was completed. The difference in mean length of hospital admission before and during the recruitment period was significantly different (p <001).

Comments: The length of hospital admission of women with threatened preterm labor is found to be reduced during the recruitment period of the APOSTEL-II trial. This shows that the conduct of a randomized controlled trial itself has the potential to change daily practice. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

Originele taal-2English
Pagina's (van-tot)8-11
Aantal pagina's4
TijdschriftEuropean journal of obstetrics gynecology and reproductive biology
Volume186
DOI's
StatusPublished - mrt.-2015

Vingerafdruk

Duik in de onderzoeksthema's van 'Impact of a randomized trial on maintenance tocolysis on length of hospital admission of women with threatened preterm labor in The Netherlands'. Samen vormen ze een unieke vingerafdruk.

Citeer dit